Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment.

Stemkens R, Litjens CHC, Dian S, Ganiem AR, Yunivita V, van Crevel R, Te Brake LHM, Ruslami R, Aarnoutse RE.

Int J Antimicrob Agents. 2019 Jun 13. pii: S0924-8579(19)30163-3. doi: 10.1016/j.ijantimicag.2019.06.010. [Epub ahead of print]

PMID:
31202922
2.

Diabetes mellitus among pulmonary tuberculosis patients from four TB-endemic countries: the TANDEM study.

Ugarte-Gil C, Alisjahbana B, Ronacher K, Riza AL, Koesoemadinata RC, Malherbe ST, Cioboata R, Llontop JC, Kleynhans L, Lopez S, Santoso P, Marius C, Villaizan K, Ruslami R, Walzl G, Panduru NM, Dockrell HM, Hill PC, Mc Allister S, Pearson F, Moore DAJ, Critchley JA, van Crevel R; TANDEM Consortium.

Clin Infect Dis. 2019 Apr 8. pii: ciz284. doi: 10.1093/cid/ciz284. [Epub ahead of print]

PMID:
30958536
3.

Enhancing the public health impact of latent tuberculosis infection diagnosis and treatment (ACT4): protocol for a cluster randomised trial.

Oxlade O, Trajman A, Benedetti A, Adjobimey M, Cook VJ, Fisher D, Fox GJ, Fregonese F, Hadisoemarto P, Hill PC, Johnston J, Long R, Obeng J, Ruslami R, Valiquette C, Menzies D.

BMJ Open. 2019 Mar 20;9(3):e025831. doi: 10.1136/bmjopen-2018-025831.

4.

Point of care HbA1c level for diabetes mellitus management and its accuracy among tuberculosis patients: a study in four countries.

Huangfu P, Laurence YV, Alisjahbana B, Ugarte-Gil C, Riza AL, Walzl G, Ruslami R, Moore DAJ, Ioana M, McAllister S, Ronacher K, Koesoemadinata RC, Grint D, Kerry S, Coronel J, Malherbe ST, Griffiths U, Dockrell HM, Hill PC, van Crevel R, Pearson F, Critchley JA.

Int J Tuberc Lung Dis. 2019 Mar 1;23(3):283-292. doi: 10.5588/ijtld.18.0359.

PMID:
30871659
5.

Latent tuberculosis infection in healthcare workers in low- and middle-income countries: an updated systematic review.

Apriani L, McAllister S, Sharples K, Alisjahbana B, Ruslami R, Hill PC, Menzies D.

Eur Respir J. 2019 Apr 18;53(4). pii: 1801789. doi: 10.1183/13993003.01789-2018. Print 2019 Apr.

PMID:
30792341
6.

Immune cell characteristics and cytokine responses in adult HIV-negative tuberculous meningitis: an observational cohort study.

van Laarhoven A, Dian S, van Dorp S, Purnama F, Koeken VACM, Diandini E, Utami F, Livia R, Apriani L, Ardiansyah E, Ter Horst R, Netea MG, Achmad TH, Hill PC, Ruslami R, Alisjahbana B, Ussher JE, Indrati A, Verrall A, Ganiem AR, van Crevel R.

Sci Rep. 2019 Jan 29;9(1):884. doi: 10.1038/s41598-018-36696-3.

7.

Intensified antibiotic treatment of tuberculosis meningitis.

Cresswell FV, Te Brake L, Atherton R, Ruslami R, Dooley KE, Aarnoutse R, Van Crevel R.

Expert Rev Clin Pharmacol. 2019 Mar;12(3):267-288. doi: 10.1080/17512433.2019.1552831. Epub 2019 Feb 12. Review.

PMID:
30474434
8.

Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa.

Grint D, Alisjhabana B, Ugarte-Gil C, Riza AL, Walzl G, Pearson F, Ruslami R, Moore DAJ, Ioana M, McAllister S, Ronacher K, Koeseomadinata RC, Kerry-Barnard SR, Coronel J, Malherbe ST, Dockrell HM, Hill PC, Van Crevel R, Critchley JA; TANDEM consortium.

Bull World Health Organ. 2018 Nov 1;96(11):738-749. doi: 10.2471/BLT.17.206227. Epub 2018 Aug 27.

9.

Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis.

Dian S, Yunivita V, Ganiem AR, Pramaesya T, Chaidir L, Wahyudi K, Achmad TH, Colbers A, Te Brake L, van Crevel R, Ruslami R, Aarnoutse R.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01014-18. doi: 10.1128/AAC.01014-18. Print 2018 Dec.

10.

Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients.

Te Brake LHM, Yunivita V, Livia R, Soetedjo N, van Ewijk-Beneken Kolmer E, Koenderink JB, Burger DM, Santoso P, van Crevel R, Alisjahbana B, Aarnoutse RE, Ruslami R; on behalf of the TANDEM Consortium.

Clin Pharmacol Ther. 2019 Mar;105(3):730-737. doi: 10.1002/cpt.1232. Epub 2018 Oct 29.

PMID:
30222857
11.

Improving the microbiological diagnosis of tuberculous meningitis: A prospective, international, multicentre comparison of conventional and modified Ziehl-Neelsen stain, GeneXpert, and culture of cerebrospinal fluid.

Heemskerk AD, Donovan J, Thu DDA, Marais S, Chaidir L, Dung VTM, Centner CM, Ha VTN, Annisa J, Dian S, Bovijn L, Mai NTH, Phu NH, Chau NVV, Ganiem AR, Van CT, Geskus RB, Thuong NTT, Ruslami R, Meintjes G, van Crevel R, Wilkinson RJ, Thwaites GE.

J Infect. 2018 Dec;77(6):509-515. doi: 10.1016/j.jinf.2018.09.003. Epub 2018 Sep 12.

12.

Use of whole-genome sequencing to predict Mycobacterium tuberculosis drug resistance in Indonesia.

Chaidir L, Ruesen C, Dutilh BE, Ganiem AR, Andryani A, Apriani L, Huynen MA, Ruslami R, Hill PC, van Crevel R, Alisjahbana B.

J Glob Antimicrob Resist. 2019 Mar;16:170-177. doi: 10.1016/j.jgar.2018.08.018. Epub 2018 Aug 29.

PMID:
30172045
13.

Disease characteristics and treatment of patients with diabetes mellitus attending government health services in Indonesia, Peru, Romania and South Africa.

Soetedjo NNM, McAllister SM, Ugarte-Gil C, Firanescu AG, Ronacher K, Alisjahbana B, Costache AL, Zubiate C, Malherbe ST, Koesoemadinata RC, Laurence YV, Pearson F, Kerry-Barnard S, Ruslami R, Moore DAJ, Ioana M, Kleynhans L, Permana H, Hill PC, Mota M, Walzl G, Dockrell HM, Critchley JA, van Crevel R; TANDEM Consortium.

Trop Med Int Health. 2018 Oct;23(10):1118-1128. doi: 10.1111/tmi.13137. Epub 2018 Sep 10.

PMID:
30106222
14.

Computer-assisted chest radiography reading for tuberculosis screening in people living with diabetes mellitus.

Koesoemadinata RC, Kranzer K, Livia R, Susilawati N, Annisa J, Soetedjo NNM, Ruslami R, Philipsen R, van Ginneken B, Soetikno RD, van Crevel R, Alisjahbana B, Hill PC.

Int J Tuberc Lung Dis. 2018 Sep 1;22(9):1088-1094. doi: 10.5588/ijtld.17.0827.

PMID:
30092877
15.

Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.

Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata RC, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion MJ, Li PZ, Hill PC, Schwartzman K, Benedetti A.

N Engl J Med. 2018 Aug 2;379(5):440-453. doi: 10.1056/NEJMoa1714283.

16.

Safety and Side Effects of Rifampin versus Isoniazid in Children.

Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, Marks GB, Long R, Elwood K, Zielinski D, Gninafon M, Wulandari DA, Apriani L, Valiquette C, Fregonese F, Hornby K, Li PZ, Hill PC, Schwartzman K, Benedetti A, Menzies D.

N Engl J Med. 2018 Aug 2;379(5):454-463. doi: 10.1056/NEJMoa1714284.

17.

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.

Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G, Requena-Méndez A, Peloquin C, Koegelenberg CFN, Alffenaar JWC, Ruslami R, Tostmann A, Swaminathan S, McIlleron H, Davies G.

J Antimicrob Chemother. 2018 Sep 1;73(9):2305-2313. doi: 10.1093/jac/dky152.

18.

Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study.

van Laarhoven A, Dian S, Aguirre-Gamboa R, Avila-Pacheco J, Ricaño-Ponce I, Ruesen C, Annisa J, Koeken VACM, Chaidir L, Li Y, Achmad TH, Joosten LAB, Notebaart RA, Ruslami R, Netea MG, Verbeek MM, Alisjahbana B, Kumar V, Clish CB, Ganiem AR, van Crevel R.

Lancet Infect Dis. 2018 May;18(5):526-535. doi: 10.1016/S1473-3099(18)30053-7. Epub 2018 Feb 3.

PMID:
29395996
19.

Latent TB infection and pulmonary TB disease among patients with diabetes mellitus in Bandung, Indonesia.

Koesoemadinata RC, McAllister SM, Soetedjo NNM, Febni Ratnaningsih D, Ruslami R, Kerry S, Verrall AJ, Apriani L, van Crevel R, Alisjahbana B, Hill PC.

Trans R Soc Trop Med Hyg. 2017 Feb 1;111(2):81-89. doi: 10.1093/trstmh/trx015.

PMID:
28419376
20.

Clinical Parameters, Routine Inflammatory Markers, and LTA4H Genotype as Predictors of Mortality Among 608 Patients With Tuberculous Meningitis in Indonesia.

van Laarhoven A, Dian S, Ruesen C, Hayati E, Damen MSMA, Annisa J, Chaidir L, Ruslami R, Achmad TH, Netea MG, Alisjahbana B, Rizal Ganiem A, van Crevel R.

J Infect Dis. 2017 Apr 1;215(7):1029-1039. doi: 10.1093/infdis/jix051.

PMID:
28419315
21.

Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies.

Marais BJ, Heemskerk AD, Marais SS, van Crevel R, Rohlwink U, Caws M, Meintjes G, Misra UK, Mai NTH, Ruslami R, Seddon JA, Solomons R, van Toorn R, Figaji A, McIlleron H, Aarnoutse R, Schoeman JF, Wilkinson RJ, Thwaites GE; Tuberculous Meningitis International Research Consortium.

Clin Infect Dis. 2017 Feb 15;64(4):501-509. doi: 10.1093/cid/ciw757. Review.

22.

Finding the right dose of rifampicin, and the right dose of optimism.

Ruslami R, Menzies D.

Lancet Infect Dis. 2017 Jan;17(1):2-3. doi: 10.1016/S1473-3099(16)30315-2. Epub 2016 Oct 26. No abstract available.

23.

Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients.

Yunivita V, Dian S, Ganiem AR, Hayati E, Hanggono Achmad T, Purnama Dewi A, Teulen M, Meijerhof-Jager P, van Crevel R, Aarnoutse R, Ruslami R.

Int J Antimicrob Agents. 2016 Oct;48(4):415-21. doi: 10.1016/j.ijantimicag.2016.06.016. Epub 2016 Jul 26.

PMID:
27526979
24.

Therapy for Tuberculous Meningitis.

van Crevel R, Ruslami R, Aarnoutse R.

N Engl J Med. 2016 Jun 2;374(22):2187. doi: 10.1056/NEJMc1602291. No abstract available.

PMID:
27248635
25.

Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.

Savic RM, Ruslami R, Hibma JE, Hesseling A, Ramachandran G, Ganiem AR, Swaminathan S, McIlleron H, Gupta A, Thakur K, van Crevel R, Aarnoutse R, Dooley KE.

Clin Pharmacol Ther. 2015 Dec;98(6):622-9. doi: 10.1002/cpt.202. Epub 2015 Oct 22.

26.

Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.

te Brake LH, Ruslami R, Later-Nijland H, Mooren F, Teulen M, Apriani L, Koenderink JB, Russel FG, Burger DM, Alisjahbana B, Wieringa F, van Crevel R, Aarnoutse RE.

Antimicrob Agents Chemother. 2015;59(6):3233-9. doi: 10.1128/AAC.03485-14. Epub 2015 Mar 23.

27.

Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis.

Te Brake L, Dian S, Ganiem AR, Ruesen C, Burger D, Donders R, Ruslami R, van Crevel R, Aarnoutse R.

Int J Antimicrob Agents. 2015 May;45(5):496-503. doi: 10.1016/j.ijantimicag.2014.12.027. Epub 2015 Feb 7.

PMID:
25703312
28.

Clinical management of concurrent diabetes and tuberculosis and the implications for patient services.

Riza AL, Pearson F, Ugarte-Gil C, Alisjahbana B, van de Vijver S, Panduru NM, Hill PC, Ruslami R, Moore D, Aarnoutse R, Critchley JA, van Crevel R.

Lancet Diabetes Endocrinol. 2014 Sep;2(9):740-53. doi: 10.1016/S2213-8587(14)70110-X. Review.

29.

Reply to "strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response".

Aarnoutse R, Ruesen C, Burhan E, van Crevel R, Ruslami R.

Antimicrob Agents Chemother. 2014;58(1):629-30. doi: 10.1128/AAC.01651-13. No abstract available.

30.

Management of children exposed to Mycobacterium tuberculosis: a public health evaluation in West Java, Indonesia.

Rutherford ME, Ruslami R, Anselmo M, Alisjahbana B, Yulianti N, Sampurno H, van Crevel R, Hill PC.

Bull World Health Organ. 2013 Dec 1;91(12):932-941A. doi: 10.2471/BLT.13.118414. Epub 2013 Sep 10.

31.

Risk factors for treatment default among adult tuberculosis patients in Indonesia.

Rutherford ME, Hill PC, Maharani W, Sampurno H, Ruslami R.

Int J Tuberc Lung Dis. 2013 Oct;17(10):1304-9. doi: 10.5588/ijtld.13.0084.

PMID:
24025382
32.

Rifampicin and moxifloxacin for tuberculous meningitis--authors' reply.

Ruslami R, Ganiem AR, Aarnoutse RE, van Crevel R; study team.

Lancet Infect Dis. 2013 Jul;13(7):570. doi: 10.1016/S1473-3099(13)70156-7. No abstract available.

PMID:
23809224
33.

Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.

Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, Donders R, van Crevel R, Aarnoutse R.

Antimicrob Agents Chemother. 2013 Aug;57(8):3614-9. doi: 10.1128/AAC.02468-12. Epub 2013 May 20.

34.

Risk factors for Mycobacterium tuberculosis infection in Indonesian children living with a sputum smear-positive case.

Rutherford ME, Hill PC, Maharani W, Apriani L, Sampurno H, van Crevel R, Ruslami R.

Int J Tuberc Lung Dis. 2012 Dec;16(12):1594-9. doi: 10.5588/ijtld.12.0389.

PMID:
23131256
35.

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.

Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, Borm G, Aarnoutse RE, van Crevel R.

Lancet Infect Dis. 2013 Jan;13(1):27-35. doi: 10.1016/S1473-3099(12)70264-5. Epub 2012 Oct 25.

PMID:
23103177
36.

Adherence to isoniazid preventive therapy in Indonesian children: A quantitative and qualitative investigation.

Rutherford ME, Ruslami R, Maharani W, Yulita I, Lovell S, Van Crevel R, Alisjahbana B, Hill PC.

BMC Res Notes. 2012 Jan 6;5:7. doi: 10.1186/1756-0500-5-7.

37.

Implications of the global increase of diabetes for tuberculosis control and patient care.

Ruslami R, Aarnoutse RE, Alisjahbana B, van der Ven AJ, van Crevel R.

Trop Med Int Health. 2010 Nov;15(11):1289-99. doi: 10.1111/j.1365-3156.2010.02625.x. Review.

38.

Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.

Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, van Crevel R.

Antimicrob Agents Chemother. 2010 Mar;54(3):1068-74. doi: 10.1128/AAC.00447-09. Epub 2009 Dec 28.

39.

A step-wise approach to find a valid and feasible method to detect non-adherence to tuberculosis drugs.

Ruslami R, van Crevel R, van de Berge E, Alisjahbana B, Aarnoutse RE.

Southeast Asian J Trop Med Public Health. 2008 Nov;39(6):1083-7.

PMID:
19062699
40.

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.

Nijland HM, Ruslami R, Suroto AJ, Burger DM, Alisjahbana B, van Crevel R, Aarnoutse RE.

Clin Infect Dis. 2007 Oct 15;45(8):1001-7. Epub 2007 Sep 4.

PMID:
17879915
41.

Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.

Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE.

Antimicrob Agents Chemother. 2007 Jul;51(7):2546-51. Epub 2007 Apr 23.

42.

Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.

Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, van der Ven AJ, Danusantoso H, Aarnoutse RE, van Crevel R.

Clin Infect Dis. 2006 Oct 1;43(7):848-54. Epub 2006 Aug 22.

PMID:
16941365
43.

Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis.

Ruslami R, Nijland H, Aarnoutse R, Alisjahbana B, Soeroto AY, Ewalds S, van Crevel R.

Antimicrob Agents Chemother. 2006 Feb;50(2):822-3. No abstract available.

Supplemental Content

Loading ...
Support Center